As shown in Table 1, there were more subjects with APOE4, type 2 diabetes mellitus (DM), hypertension, coronary heart disease (CHD) and metabolism syndrome (MS) in the aMCI and naMCI groups than in the control group at baseline (P < 0.05). This evidence concerns the gene APOE and diabetes mellitus.